

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Nuclear Scan, PSC	In accordance with letter dated July 18, 2019.	4. Expiration Date: December 31, 2026
2. P.O. Box 367580 San Juan, PR 00936-7580	3. License number: 52-31182-01 is amended in its entirety to read as follows:	5. Docket No.: 030-37326 Reference No.:

- | | | | |
|---|----------------------------------|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| A. Any byproduct material permitted by 10 CFR 35.100 | A. Any | A. As Needed | A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. |
| B. Any byproduct material permitted by 10 CFR 35.200 | B. Any | B. As Needed | B. For use in imaging and localization studies permitted by 10 CFR 35.200. |
| C. Iodine-131 permitted by 10 CFR 35.300 | C. Any | C. 500 millicuries total | C. For any iodine-131 use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75. |

CONDITIONS

10. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at the licensee's facilities located at
- A. Centro de Medicina Nuclear de Guaynabo, Calle Carazo #11, Guaynabo, Puerto Rico, 00969

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-31182-01

Amendment No. 6

Docket or Reference Number
030-37326

B. Centro Medicina Nuclear de Las Piedras, Highway 198, KM 23.6, Coyores, Las Piedras, Puerto Rico, 00771

11. The Radiation Safety Officer for this license is David Rhoe, M.S.

12. Licensed material shall only be used by, or under the supervision of:

A. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Juan Fontanez Nieves, M.D.

35.100; 35.200; Oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

52-31182-01

Amendment No. 6

Docket or Reference Number

030-37326

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated September 9, 2016 [ML16286A500]
- B. Letter dated November 29, 2016 [ML16354A285]
- C. Letter received April 16, 2019 [ML19116A022]
- D. Letter dated July 18, 2019 [ML19232A184]

Date: October 3, 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Shawn Seeley
Region 1